Biocompatible emulsion system makes a difference.
Vision
Deliver more effective and more biocompatible new products.
Mission
Contribute to people’s quality of life through applied science in water soluble emulsion technology.
Value
Relentless efforts to pursue technological breakthrough.
Compelling reasons to choose us!!!
- Possess a group of engineers who are patented with drug delivery system especially many water-soluble emulsion technologies.
- The technology that developed the world’s first “long term stable and highly absorbable Ubiquinol 40% water-soluble Coenzyme Q10”.
- Ability to apply water-soluble emulsion technology established for Coenzyme Q10 to other poorly water-soluble substances.
- Stable production capacity that continues to produce high-quality products in accordance with HACCP.
- Possess ability to collect world's most recent raw ingredients information and develop new technology in such a short time.
Evolution of Coenzyme Q10 Reason.01
Japan’s water-soluble emulsion technology becomes world standard Reason.02
Ubiquinol CoQ10 is a component discovered in the United States in 1957, and is used in a wide range of fields as pharmaceuticals and supplements.
Ubiquinol CoQ10 is easily oxidized, unstable and oil-soluble, so it had no choice but to be made into soft capsule.
Therefore, Ubiquinol 40% water-soluble CoQ10(ShiroQ) was developed to ensure that Ubiquinol CoQ10 is stable and efficiently absorbed by the body.
We are committed to meet various demands from our customers with water-soluble emulsion technology.
The proposal of PetroEuroAsia Reason.03
Evolving from old soft capsule.
(Excerpt from a paper on the difference in the bioavailability of between soft capsule and Ubiquinol 40% water-soluble CoQ10.)
In this study, we showed the bioavailability of Ubiquinol 40% water-soluble CoQ10. Two groups of 5 healthy young subjects received single oral administration of 100 mg of QH in the form of a soft capsule containing QH dissolved in safflower oil or Ubiquinol 40% water-soluble CoQ10 in the fasting period, and changes in the plasma QH concentration were monitored over time.
Fig.1 shows the changes in plasma ubiquinol concentrations after single oral administration. The plasma QH concentration before administration was 0.68±0.08㎍/ml. Tmax was 6 hours after the administration. Cmax values compared with the pre-administration baseline in the soft capsule and Ubiquinol 40% water-soluble CoQ10 groups were 0.4±0.21 and 0.89±0.27㎍/ml, respectively, and AUC0-24hr values were 3.59±1.63 and 9.68±2.35㎍h/ml, respectively. Ubiquinol 40% water-soluble CoQ10 of QH exhibited superior bioavailability even when administered in the fasting period.